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ABSTRACT 
Swine respiratory diseases are of major concern to pork producers because of economic 
consequences related to reduced productivity, increased mortality, and the higher costs 
associated with prevention, control, treatments, and diagnoses.  Actinobacillus 
pleuropneumoniae (APP) is the causative agent of porcine pleuropneumonia, a respiratory 
disease found throughout the world.  Pigs are the primary host of APP and infection can 
occur at any age.  APP infections are often acute and rapidly fatal, but chronic and/or 
subclinical infections occur.  In particular, the latter play a role in perpetuating endemic 
infections in populations.   
 
A plethora of methods have been developed for the detection and/or diagnosis of APP, e.g., 
bacterial culture, antibody-based assays, and detection of nucleic acid targets using PCR.  In 
particular, antibody detection provides an efficient, cost-effective approach for the 
surveillance of swine populations and several antibody assays have been developed, 
including ELISA assays based on polysaccharide antigen (capsular and LPS) and tests based 
on the detection of anti-toxin antibodies Apx I, ApxII, ApxIII, and ApxIV.   
 
Research has shown that the use of oral fluid specimens in diagnosis provides several 
advantages compared serum, including easier sample collection and better herd-level 
sensitivity and specificity (Olsen et al., 2013).  Within this context, the focus of this thesis 
was on the development of an antibody ELISA for the detection of Actinobacillus 
pleuropneumoniae (APP) ApxIV toxin antibodies in swine oral fluid specimens.   
 
As described in Chapter 3, antibody responses specific for ApxIV in serum and oral fluid 
were compared in pigs inoculated with APP serovars 1, 5, 7, or 12 under experimental 
conditions using a commercial ApxIV antibody ELISA.  The detection of antibodies in the 
oral fluid was achieved by adapting the serum ELISA protocol was adapted to the oral fluid 
matrix, as has been previously described (Kittawornrat et al., 2013).  Serum samples were 
collected weekly and oral fluid samples were collected daily from individual pigs from day 
post inoculation (DPI) -14 through DPI 56.  The LPS ELISA serum response showed that all 
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pigs exposed to serovars 1 and 7 were positive from DPI 14 through DPI 56, with some 
animals demonstrating a LPS-specific IgG response as early as 7 DPI.  In contrast, the LPS 
antibody response was transient or absent in pigs inoculated with serovars 5 and 12, 
suggesting that inoculation of pigs did not result in infection.  Both IgM and IgG ApxIV 
serum antibody was detected in animals infected with serovars 1 and 7.  Likewise, oral fluid 
samples from these animals showed a significant (p < 0.05) ApxIV IgG response.  Thus, this 
pilot experiment suggested that ELISAs based on the detection of ApxIV IgG antibody in 
oral fluid samples could be developed.  Future work will be required to establish the ApxIV 
oral fluid ELISA cutoff and evaluate the application of the assay in the field.   
 
REFERENCES 
Kittawornrat A, Engle M, Panyasing Y, Olsen C, Schwartz K, Ballagi A, Rice A, Lizano S, 
Wang C, Zimmerman J (2013).  Kinetics of the porcine reproductive and respiratory 
syndrome virus (PRRSV) humoral immune response in swine serum and oral fluids 
collected from individual boars.  BMS Vet Res 9:61. 
Olsen C, Wang C, Christopher-Hennings J, Doolittle K, Harmon K, Abate S, Kittawornrat A, 
Lizano S, Main R, Nelson E, Otterson T, Panyasing Y, Rademacher C, Rauh R, Shah R, 
Zimmerman J (2013).  Probability of detecting PRRSV infection using pen-based swine 
oral fluid specimens as a function of within-pen prevalence.  J Vet Diagn Invest 25:328-
335. 
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CHAPTER 1.  THESIS ORGANIZATION 
This thesis consists of 3 chapters.  The Chapter 1 describes the organization of the thesis and   
Chapter 2 is a review entitled “An update on Actinobacillus pleuropneumoniae”.  Chapter 3, 
“Detection of Actinobacillus pleuropneumoniae ApxIV toxin antibody in serum and oral 
fluid specimens from pigs inoculated under experimental conditions” was submitted for 
publication in the Journal of Veterinary Diagnostic Investigation.  The tables and figures 
associated with each chapter follow the references.  The final chapter contains the General 
Conclusions of the thesis. 
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CHAPTER 2.  AN UPDATE ON ACTINOBACILLUS PLEUROPNEUMONIAE 
Wendy Mencía González Guzmán, DVM 
 
INTRODUCTION 
The genus Actinobacillus is a small, gram-negative, pleomorphic, non-spore-forming, 
coccoid-to-rod-shaped group of bacteria in the Pasteurellacea family.  The genus is 
facultatively anaerobic and has complex nutritional requirements (MacInnes and Bossé, 
2004).  The bacteria in genus Actinobacillus are always associated with mucous membranes 
and have a limited host range (MacInnes and Lally, 2006). 
 
Actinobacillus pleuropneumoniae (APP) was first described as the cause of pneumonic 
lesions in pigs experimentally inoculated with classical swine fever virus and was classified 
at that time as a Haemophilus-like bacterium (Pattison et al., 1957).  Later, an investigation 
of acute, fatal, respiratory disease in swine farms in Argentine led to a bacterium identified as 
Haemophilus pleuropneumoniae (Shope, 1964a).  H. pleuropneumoniae was also shown to 
cause acute pneumonia when inoculated into pigs under experimental conditions (Shope et 
al., 1964b).  Because of its growth requirements and hemolytic characteristics, APP was 
originally considered a member of the Haemophilus organisms of humans and thought to be 
synonymous with H. parahaemolyticus (Zinnemann, 1971).  Killian (1976) separated this 
bacterium from the human Haemophilus spp. on the basis of biochemical characteristics, 
phenotypic differences, and it pathogenicity for swine.  Later, Kilian et al (1978) proposed 
the name originally given by Shope (1964a) for the causal agent of porcine pleuropneumonia.  
The organism was finally placed in the genus Actinobacillus based on DNA homology 
studies (Pohl et al., 1983). 
 
Two APP biotypes have been identified on the basis of the nicotinamide adenine dinucleotide 
(NAD or V-factor) requirement for growth: biotype I (NAD-dependent) and biotype II 
(NAD- independent) (Pohl et al., 1983).  Based on the composition of the capsular 
polysaccharide (CPS), the two biotypes have been divided into 15 serovars.  Biotype I 
includes 13 serotypes (1-12, 15) and biotype II contains 2 serotypes (13-14) (Blackall et al., 
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2002; Perry et al., 1990).  Serotypes 1 and 5 are further differentiated into 1a and 1b, and 5a 
and 5b, based on minor differences in the polysaccharide structures (Jolie et al., 1994; 
Nielsen, 1985).  Recently, a 16th serotype was proposed following the recovery of an APP 
isolate that did not fit the current classification criteria from swine with pleuropneumonia 
(Sarkoezi et al., 2015). 
 
Closely related bacterial species also are found in swine and must be differentiated from 
APP.  Actinobacillus suis, first described in 1962, is an early colonizer of the upper 
respiratory tract of swine (van Dorssen and Jaartsveld, 1962; MacInnes and Lally, 2006).  A. 
suis is usually associated with septicemia and sudden death in young piglets, but may also be 
found in weaned pigs (Gottschalk, 2012).  It shares characteristics with APP, including iron 
binding proteins (TbpA and TbpB), urease positivity, and the production of RTX toxins 
(ApxI and ApxII) (MacInnes and Bossé, 2004). 
 
More recently, Gottschalk et al (2003) reported the description of two APP-like isolates 
(9953L55 and 0347) that were antigenically and biochemically similar to APP serovars 1 and 
9, respectively, but did not produce clinical disease or lesions after experimental inoculation 
of pigs and were genetically distinct from APP.  On that basis, a new Actinobacillus species 
was proposed (Actinobacillus porcitonsillarum).  A porcitonsillarum has since been 
identified in Spain (Martinez and Maldonado, 2006), Thailand (Tonpitak et al., 2007), and 
Japan (Ohba et al., 2007). 
 
SUSCEPTIBLE SPECIES 
Pigs are the primary host of APP and infection can occur at any age (Gottschalk, 2012).  APP 
is an obligate parasite and is typically isolated from lungs, nasal secretions, and tonsils of 
infected pigs (Auger et al., 2009; Chiers et al., 1999; Dom et al., 1994; Gottschalk, 2012).  
However, there are a few reports describing the recovery of APP from other sites, e.g., 
secretions from pigs with otitis media (Duff et al., 1996) and from the joints of pigs with 
osteomyelitis (Jensen et al., 1999). 
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APP infections are not limited to swine in commercial production settings.  Thus, Štukelj et 
al (2014) reported 28.3% of 184 samples collected from wild boar (Sus scrofa) in Slovenia 
were seropositive to APP.  Likewise, Marinou et al (2015) reported that 90.5% of the 
samples collected from wild boar in Greece were seropositive for APP.  In the United States, 
Baroch et al (2015) found that 69.7% of the feral swine sampled were serologically positive 
for APP.  Cumulatively, these reports suggest that APP infections are common in feral swine.  
For that reason, feral swine should be considered a reservoir of APP and a potential source of 
infection for domestic swine. 
 
Although swine are the natural host, APP has occasionally been recovered from cattle, deer, 
and sheep (see reviews by Desrosiers et al., 1998 and Dubreuil et al., 2000).  Hervás et al 
(1996) reported that APP was associated with pneumonic lesions in lambs in Spain.  Pérez et 
al (2014) reported the detection of APP by PCR in layer hens with signs of infectious coryza 
(Avibacterium paragallinarum).  These reports are of interest, but they are not of sufficient 
weight to support the concept that non-porcine species are significant in the epidemiology or 
ecology of APP. 
 
VIRULENCE FACTORS AND PATHOGENESIS 
As general rule, bacteria cause disease by two mechanisms: tissue invasion and toxin 
production (Post, 2012).  The virulence of A. pleuropneumoniae is multifactorial and there 
are several products (secreted factors) as well as bacterial structures involved in its 
pathogenesis.  The role of APP virulence factors in these mechanisms has been reviewed in 
detail elsewhere (Bossé et al., 2002; Chiers et al., 2010).  A summary of the major 
contributors to APP pathogenesis is presented below. 
 
Surface polysaccharides 
The capsular polysaccharide (CP) is a major structural cell component and the basis for 
serovar specificity (Inzana, 1991; Perry et al., 1990).  The CP is considered an important 
virulence factor in APP infections and is involved in protecting the bacteria from antibody 
and preventing phagocytosis (Inzana et al., 1988; Rioux et al., 2000; Ward et al., 1994).  That 
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is, greater production of CP by an APP strain is correlated with more extensive pulmonary 
lesions and greater resistance to killing (Bandara et al., 2003; Ward and Inzana, 1997).  
Interestingly, Van Overbeke et al (2002) reported that APP growth conditions altered the 
production of CP, which in turn affected the expression of surface antigens involved in the 
adhesion.  
 
Lipopolysaccharide (LPS) is a complex biomolecule divided into three regions: lipid A, 
anchored in the outer membrane; the core oligosaccharide, and the O-antigen, a 
polysaccharide chain composed of repeated units (Wang and Quinn, 2010).  Three types of 
APP LPS structures have been described:  smooth (serovars 2, 4, and 7), rough (serovars 3 
and 6), and semi-rough (serovars 1 and 5).  This results in differences in the gross appearance 
of colonies (Byrd and Kadis, 1989).  Although the composition of LPS differs among APP 
serovars, antibody cross-reactions occur among serovars 1, 9, and 11; 3, 6, and 8; and 4 and 7 
because of similarities in the O-antigen (Perry et al., 1990).   
 
LPS has been shown to play a role in the adherence of APP to the epithelial cells of the 
respiratory tract (Bélanger et al., 1990; Paradis et al., 1999) and contributes to APP-
associated respiratory disease by enhancing the effect of Apx toxins on phagocytes (Ramjeet 
et al., 2005).  Bélanger et al (1990) reported that adhesion of APP to tracheal epithelium was 
higher in isolates with a smooth versus semi-rough LPS.  Other studies demonstrated that the 
LPS outer core affected APP adhesion and virulence (Ramjeet et al., 2005; 2008a).  
Specifically, the absence of terminals for galactose (Gal I) and D, D Heptose (Hep IV) in the 
outer core resulted in the loss of the ability to adhere to respiratory tract cells and greater 
susceptibility to antimicrobial peptides (Ramjeet et al., 2005). 
 
The formation of biofilms has been demonstrated in APP isolates and reportedly has 
relevance to colonization and pathogenesis (Kaplan and Mulks, 2005).  Recent work 
demonstrated that the lack of O-antigen reduced the ability of APP to form biofilms 
(Hathroubi et al., 2015).  More specifically, the deletion of genes involved in biofilm 
formation (arcA, luxS, hns) resulted in the attenuation of virulence (Buettner et al., 2008; 
Dalai et al., 2009; Li et al., 2008).  As discussed by Chiers et al (2010), biofilms increase 
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APP resistance to antimicrobials agents and to the host’s immune response by interfering 
with macrophage phagocytic activity and inhibiting antibody access to the cell surface.   
 
Exotoxins 
Four APP exotoxins (Apx I, II, III, and IV) have been described (Frey, 1995; Schaller et al., 
1999).  These RTX (Repeats in the structural ToXin) pore-forming toxins have cytotoxic or 
cytolytic effects on epithelial cells, endothelial cells, red blood cells, neutrophils, and 
macrophages (Frey, 1995, 2011; Schaller et al., 2000).  Not all serovars produce all toxins 
(see Table 2); with the exception of ApxIV, which is produced universally.  ApxIV is 
generally thought to be produced only during infection (Deslandes et al., 2010; Schaller et 
al., 1999), but a study analyzing a DIVA subunit vaccine reported the expression of the 
ApxIVA gene under in vitro conditions (Buettner et al., 2011).  Although their exact 
contribution to the pathogenesis of APP is not clear, virulence is related to Apx production 
(Beck et al., 1994; Frey, 1995).  In general, Apx exotoxins are thought to be involved in the 
evasion of host defense mechanisms and in the induction of lung lesions (Dom et al., 1994; 
Frey, 2011; Haesebrouck et al., 1997; Kamp et al., 1997).   
 
Transferrin binding proteins 
If unable to acquire sufficient iron, APP will be unable to grow and will be eliminated by 
host defense mechanisms or succumb to nutrient deficiency (Ratledge and Dover, 2000).  
The concentration of iron in the extracellular environment of the host is not adequate, but 
APP has developed compensatory mechanisms for iron acquisition (Ratledge and Dover, 
2000).  Lipid A of the LPS has been associated with the nutrient acquisition, specifically with 
iron uptake (Bossé et al., 2002; Chiers et al., 2010).  In addition, APP expresses two 
transferrin-binding proteins (TbpA and TbpB) that enable it to use porcine transferrin as 
source of iron (Baltes et al., 2002).  Several studies have reported that these transferrin 
binding proteins play a role in APP virulence (Baltes et al., 2002; Bossé et al., 2002; Chiers 
et al., 2010; Haesebrouck et al., 1997). 
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Other factors 
As reviewed elsewhere, (Bossé et al., 2002; Chiers et al., 2010; Haesebrouck et al., 1997; 
Inzana, 1991), a number of outer membrane proteins are thought to contribute to virulence.  
Some have been shown to play a role in the adhesion of APP to the respiratory tract (Baltes 
and Gerlach, 2004; Mullen et al., 2008) and others to the acquisition of the nutrients 
necessary for proliferation (Deneer and Potter, 1989; Lone et al., 2009).  Additionally, type 
IV fimbriae have been observed in APP isolates (Dom et al., 1994; Zhang et al., 2000).  This 
type of fimbriae has been associated with adhesion, colonization and survival of APP in the 
porcine respiratory tract (Boekema et al., 2004; Deslandes et al., 2010; Negrete-Abascal et 
al., 2003). 
 
Differences in virulence among and within serovars 
All APP serovars are considered pathogenic, i.e., capable of causing disease and mortality, 
but differences in virulence are observed among and within serovars (Frey, 1995).  In 
general, serovars 1, 5, 9, and 11 are considered the most virulent; serovars 2-4, 6-8, 12, and 
15 are considered moderately virulent; and serovars 10, 13, and 14 the least virulent (Frey, 
2003; Komal and Mittal, 1990).  Differences in virulence are primarily associated with the 
specific bacterial structures discussed above and RTX exotoxin production patterns (Beck et 
al., 1994; Frey, 2003; Frey and Nicolet, 1990).  Production of ApxI and ApxII are considered 
to be primarily responsible for full APP virulence (Reimer et al., 1995), but Kamp et al 
(1997) demonstrated that ApxI and ApxIII were involved in the production of clinical signs 
and lung lesions for pleuropneumonia.  ApxIV, which is produced by all APP serovars, is 
considered necessary for the full expression of virulence, through mechanism(s) that have not 
yet been described (Liu et al., 2009).  Thus, the expression of more than one Apx, in addition 
to ApxIV, is correlated with the increased virulence (Beck et al., 1994; Frey, 1995, 2003).   
 
GEOGRAPHIC DISTRIBUTION 
The geographic distribution of APP serovars is summarized in Table 1.  As reviewed by 
Gottschalk (2012), APP infections in pigs have been reported in Europe, Asia, North 
America, Latin America, and Australia.  Although poorly documented, APP infections are 
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reported to occur in Africa, as well (Veary, 1989).  Thus, APP infections occur wherever 
swine are found.   
 
As discussed by Gottschalk (2015a), information concerning the country-specific distribution 
of APP serovars is lacking or out of date, despite the fact that knowing which serovars are 
present in a region is essential information for the diagnosis and control of the disease.  In 
general, APP biotype II is associated with the majority of outbreaks in Europe, while APP 
serovars belonging to biotype I are more common in America and Asia (Gottschalk, 2012).   
 
Within any region, the predominant APP serovars may change over time.  For example, 
serovars 2 and 5 were the most common in Korea between 1995 and 2010 (Yoo et al., 2014), 
but Lee et al (2015) recently reported that serovar 1 and 5 were dominant in Korea, i.e., 
serovar 1 had replaced serovar 2.  Lee et al (2015) hypothesized that this change could be due 
to intensive serovar-specific vaccination.  That is, vaccination may decrease APP-related 
morbidity and mortality, but does not provide cross-protection to multiples serovars.  In a 
similar vein, MacInnes et al (2008) and Gottschalk and Lacouture (2015b) reported a 
reduction in infections with APP serovars 1 and 5 over time and an increase in infections 
with serovars 7 and 12 in Ontario (Canada) herds.  The authors suggested that this change 
resulted from improved farm management, e.g., more testing and monitoring, better 
biosecurity, more all-in/all-out management, and less commingling of animals from multiple 
sources.  In addition, this change may reflect the impact of a program for the control of APP 
serovars 1 and 5 in breeding stock implemented by the provincial government of Ontario.   
 
IMPACT ON SWINE HEALTH 
The clinical expression of APP ranges from peracute death to chronic subclinical infection 
depending on the serovar, the immune status of the host, and exposure dose (Bossé, 2002; 
Deslandes, 2010; Gottschalk, 2012; MacInnes and Bossé, 2004; Marsteller and Fenwick, 
1999).  APP infections can also affect pig health through interactions with other factors 
(Bochev, 2007).  For example, subclinical APP can disrupt normal host metabolic processes 
and optimal nutrient utilization, thereby affecting pig performance parameters, e.g., weight 
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gain, pregnancy, lactation, and others (Dial, 2002).  Thus, the economic impact of APP in 
commercial swine production may be the result of acute mortality (often in late finishing), a 
reduction in productivity parameters, and costs associated with diagnostics and the 
implementation of control measures (Gottschalk, 2012; Losinger et al., 1998).  Losinger 
(2005) estimated the cost of measures for the control of APP infections in the U.S at $32 
million dollars in 1995 (more recent estimates are not available). 
 
In reality, estimates of the economic impact of APP on swine production are confounded by 
the fact that APP commonly occurs concurrently with other respiratory infections in the 
“porcine respiratory disease complex” (PRDC) (Thacker and Thanawongnuwech, 2008).  
PRDC is defined as a multifactorial respiratory disease involving both bacterial and viral 
agents in grower-finisher pigs and characterized by decreased growth rates, reduced feed-
conversion, anorexia, fever, cough, and dyspnea (Brockmeier et al., 2002; Hansen et al., 
2010; Opriessnig et al., 2011).  The distribution and severity of the disease is thought to 
involve several predisposing determinants including interactions among infectious agents, 
environmental factors, production and management factors, and host determinants, e.g., 
immune status and age (Bochev, 2007; Opriessnig et al., 2011).  Infectious agents involved in 
PRDC can include primary pathogens, i.e., those agents capable of causing disease as single 
infections, and opportunistic pathogens that interact synergistically with primary pathogens 
(Brockmeier et al., 2002).  Depending on the region, primary viral agents may include 
porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 
(PCV2), swine influenza virus (SIV), classical swine fever (CSF), pseudorabies virus (PRV), 
and paramyxoviruses (PMV) (Thacker, 2008; Bochev, 2007; Opriessnig et al., 2011).  
Primary bacterial pathogens can include Mycoplasma hyopneumoniae, Bordetella 
bronchiseptica, and Actinobacillus pleuropneumoniae (Thacker, 2008; Brockmeier et al., 
2002).   
 
TRANSMISSION 
Transmission from the pathogen’s perspective is the successful completion of a series of 
challenges that begin with the exit of an infectious agent from one host and end with its 
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replication in a new, susceptible host (Zimmerman, 2003).  In the case of APP, transmission 
is considered to occur pig-to-pig, by infectious airborne droplets, or via fomites.  
Transmission is not synonymous with disease.  Thus, Hensel et al (1995) reported that 
experimental aerosol exposure to low concentrations of APP led to infection without clinical 
signs.  Particularly for APP, respiratory disease is the result of interactions among a number 
of factors, not just with the presence of the agent (Stäk, 2000).  This comment is germane 
because interpretation of the results of experiments attempting to understand the mechanisms 
of APP transmission can be affected by the serovar(s) included in the experiment, the 
immune status of the host, and the exposure dose (Bossé, 2002; Deslandes, 2010; Gottschalk, 
2012; MacInnes and Bossé, 2004; Marsteller and Fenwick, 1999).  APP’s dose dependency is 
particularly challenging and transmission by experimental inoculation is a balance between 
achieving an infectious dose while avoiding excessively severe clinical signs and/or mortality 
(Sebunya et al., 1983).   
 
Shedding of APP 
APP colonizes the lower respiratory tract, but has also been shown to persist in the upper 
respiratory tract (Bossé, 2002; Chiers et al., 2010; Dom et al., 1994).  There are no reports in 
the literature describing the detection of APP in semen, milk, feces, or urine. 
 
Several studies suggested that tonsil colonization may play an important role in the 
transmission of the disease.  Chiers et al (1999) found APP associated with the crypt wall 
epithelium of the pharyngeal tonsils and APP has been found in the tonsils of subclinically-
infected pigs (Gottschalk, 2012).  Velthuis et al (2002) showed that pigs carrying APP in 
tonsils were more likely to be infectious.  
 
Shedding of APP through nasal secretions is considered a primary exit route for the 
bacterium (Gottschalk, 2012).  In a transmission trial, Velthuis (2003) reported that the 
infectivity of APP was 6.13 times higher when more than 10 APP colonies were isolated 
from nasal swabs.  In the field, Willson (1987) reported that the maximum isolation of APP 
from nasal secretions was in animals of 12 week of age; by the 15 weeks of age the bacteria 
could not be isolated.  In a vaccination trial, Wongnarkpet et al (1999) reported peak 
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detection at 11 weeks of age and concluded that APP was more likely to be isolated from 
pigs at 4-11 week of age.   
 
Exposure route and dose  
Transmission of APP is believed to commonly occur via infectious airborne droplets over 
short distances between infected and susceptible pigs (Gottschalk, 2012; Sebunya and 
Saunders, 1983).  Aerosol transmission of a disease can occur if two requirements are met:  
1) an infectious aerosol is created and 2) susceptible animals inhale particles or droplet nuclei 
containing sufficient numbers of viable pathogen so as to achieve an infectious dose (Stärk, 
1999).  Airborne transmission of APP has been reported to occur over short distances on 
farms.  Torremorell et al (1997) found evidence that aerosol-exposed animals were 
seropositive to APP serovars 1 and 5 and concluded that APP was transmitted by air over a 
distance of 1 meter.  Similarly, Jobert (2000) reported the airborne transmission of APP 
serovar 9 over a distance of 2.5 meters.  The question of airborne transmission off APP over 
longer distances has also been addressed.  Kristensen et al (2004) found that APP airborne 
transmission between pig units was possible, but the probability of transmission was < 2% 
under field-like condition.  Tobias et al (2014) quantified APP aerosol transmission in 
weaned pigs on a farm endemically infected with serovar 2 and found the transmission rate 
within pens was ten times higher than between pens. 
 
In the field, APP transmission from infected sow to offspring occurs via close contact.  
Maternal immunity persist in piglets from 2 to 8 weeks (Cruijsen et al., 1995; Gottschalk, 
2012).  For this reason, the appearance of clinical signs is unlikely at this age.  Presumably, 
piglets that become infected from their dams become carriers and spread the infection post-
weaning (Chiers et al., 2002; Gottschalk, 2012; Vigre et al., 2002).   
Under experimental conditions, intranasal (IN) inoculation is a common route of exposure, 
but outcomes are variable, ranging from not achieving infection (Baarsch et al., 2000; Costa 
et al., 2011; Dom et al., 1994; Velthuis et al., 2002) to severe clinical signs, typical lesions of 
pleuropneumonia, and high mortality rates (Gómez-Laguna et al., 2014; Jobert, 2000; Marois 
et al., 2009; Tobias et al., 2014).  The inconsistency observed with IN inoculation may be 
because some of the inoculum enters the esophagus, rather than the respiratory tract and/or 
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because the inoculum is given once, rather than the multiple exposures that occur in the field 
(Baarsch et al., 2000; Velthuis et al., 2002).  Endobronchial inoculation has also been used 
under experimental conditions (Baarsch et al., 2000; Kamp et al., 1997).   
 
Environmental stability 
An experiment by del Río et al (2003) demonstrated the viability of APP in different 
transport systems stored at 4°C.  In liquid media, APP was viable for 13 days in brain heart 
infusion and 23 days in horse serum with 0.01% NAD.  In commercial transport systems 
designed for aerobic organisms, 54.2% of APP was viable after two days.   
 
Loera-Muro et al (2013) reported the recovery of viable APP for at least 3 weeks at 20°C.  
Assavacheep and Rycroft (2013) reported the recovery of APP held at -20°C and -70°C for 
more than 17 weeks and concluded that viable APP could persist in frozen carcasses.  They 
also demonstrated that the environmental stability of APP was improved in aqueous 
suspensions in the presence of NaCl and mucin, i.e., a model for nasal secretions.  Under dry 
conditions, APP remained viable for more than 3 days in non-absorbent materials, suggesting 
a possible indirect transmission through fomites.   
 
There are relatively few studies on viable APP in the farm environment.  Recently, Loera-
Muro et al (2013) reported the detection of APP in drinking water on swine farms by indirect 
immunofluorescence.  The viability of the bacteria was confirmed by the Live/Dead® 
BacLight stain™ (Loera-Muro et al., 2013).  Further, biofilm-like structures were found in 
the water using scanning electron microscopy.  As reviewed previously, APP uses the 
biofilm structure to attach to surfaces and as strategy for survival in the environment (Jacques 
et al., 2010; Labrie et al., 2010).  In a subsequent study, Loera-Muro et al (2014) found 
viable APP using a polymerase chain reaction test (PCR) in feed, air, and soil samples.  
Based on these findings it may be concluded that the environment can serve as reservoir for 
APP.  In endemically-infected herds, the pattern of APP-associated clinical signs and 
mortality could be explained by increasing levels of environmental contamination over time 
and exposure of animals to successively higher doses.   
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Transmission within and between herds 
The transmission of APP between herds is generally attributed to the introduction of carrier 
animals.  However, research on the environmental stability of APP (reviewed above) also 
suggests that fomites (people, equipment, vehicles) could play an important role in the 
indirect transmission of APP between and within farms (Desrosiers and Moore, 1998).  This 
is an area that merits more research. 
 
Once APP enters a population, it circulates among animals by direct (nose-to-nose) and 
indirect (aerosols and fomites) transmission.  Colonization of tonsils and excretion of APP 
from the upper respiratory tract is considered important for transmission (Chiers et al., 1999; 
Velthuis et al., 2002).  Sows can infect their offspring during lactation, but infected pigs do 
not typically develop clinical disease until maternal antibodies wane at 6 to 12 weeks of age 
(Vigre et al., 2002).  In the presence of maternal antibody, infected pigs replicate APP in 
nasal cavities and tonsils and nasal cavities become a source of infection (Chiers et al., 2001).  
These pigs do not always mount an immunological response against APP, which makes their 
detection more difficult (Chiers et al., 2010).  Thus, animals that have survived the infection, 
animals that have been infected by exposure to low doses of the bacterium, or animals with 
maternal antibody can become subclinical carriers and silently spread the infection among 
the population (Velthuis et al., 2002).   
 
Wildlife often plays a role in the diseases of domestic animals and this is probably true for 
APP, as well (Gortázar et al., 2007).  In the U.S., Baroch et al (2015) reported the detection 
of serum antibodies against porcine reproductive syndrome virus (2.5%), porcine circovirus 
type 2 (25.3%), Mycoplasma hyopneumoniae (19.7%), and APP (69.7%) in samples from 
feral swine.  Touloudi et al (2015) reported antibodies against porcine reproductive syndrome 
virus (12.8%), porcine circovirus type 2 (19.1%), and APP (57.4%) in wild boars in Greece.  
Similarly, Štukelj et al (2014) reported the detection of antibodies against Aujeszky's disease 
virus (45.1%), porcine circovirus type 2 (89.7%), Mycoplasma hyopneumoniae (15.8%), and 
APP (28.3%) in serum from wild boars in Slovenia.  These studies support the concept that 
feral swine populations present an on-going risk for the introduction of APP and other 
infectious diseases into commercial swine populations (Corn et al., 2005, 2009).   
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PREVENTION AND CONTROL 
Vaccines 
A number of vaccines have been developed and used, but the prevention and control of APP 
through vaccination has been a challenge (Gottschalk, 2012; Haesebrouck et al., 2004; 
Ramjeet et al., 2008b).  Several antigens have been evaluated as vaccine candidates, 
including Apx toxins (Van Overbeke et al., 2001), LPS and capsular polysaccharide (Byrd 
and Kadis, 1992), outer membrane proteins (Oldfield et al., 2008), autotransporter proteins 
(Oldfield et al., 2009), DNA vaccines (Chiang et al., 2009; Lu et al., 2011), subunit vaccines 
(Buettner et al., 2011), and mutant vaccines (Inzana et al., 1993; Liu et al., 2007).  Despite 
the many vaccines and vaccination protocols that have developed, there is not one vaccine 
that is efficacious against all serovars.  Therefore it is recommended that the serovar present 
in the population be taken into account, if vaccination is used as a control measure (Vanni et 
al., 2012).   
 
Antibiotics 
If used sufficiently early in the course of the infection, antimicrobial agents have been used 
to control APP in pig production with relatively good success.  However, even if treated, 
chronically-infected animals may not recover and will remain as carriers (Gottschalk, 2012; 
Willson and Osborne, 1985).  A point of concern is that fact that increasing resistance of APP 
to antimicrobials has been reported.  For example, Matter et al (2007) reported that APP 
isolates from slaughtered pigs were resistant to sulfamethoxazole, a sulfamethoxazole-
trimethoprim combination, tiamulin, tilmicosin, tetracycline, penicillin, and ampicillin.  
Likewise, Vanni et al (2012) reported that APP isolates from farms in Italy were resistant to 
amoxicillin, amoxicillin/clavulanic acid, cefquinome, cotrimoxazole, penicillin G, ampicillin, 
and tilmicosin, and were decreasingly susceptible to gentamycin and marbofloxacin.  These 
reports, particularly in the context of increasing restrictions on veterinary access to 
antimicrobial agents, are of serious concern.  
 
15 
 
 
 
Diagnosis and surveillance 
The application of laboratory methods to the diagnosis and/or surveillance of APP have been 
extensively reviewed in several recent publications (Broes et al., 2007; Gottschalk, 2012, 
2015a; Żmudzki et al., 2015).  Herein we offer a brief summary of the main approaches used 
to identify APP infections.   
 
Traditionally, the diagnosis of APP on farms has focused on the observation of clinical signs 
and the isolation of APP from tissues post mortem (Gottschalk, 2012).  Detection may be 
adversely affected by sample transportation issues or with the technique used to grow the 
bacterium (Broes et al., 2007; Willson et al., 1987).  However, this classic approach is useful 
when clinical signs are present and is likely to be successful when the bacterium is present in 
sufficient numbers in clinical specimens.  This approach is not practical for identifying 
subclinical carriers and is not useful in monitoring progress in the clean-up of endemically-
infected herds.   
 
The use of antibody-based assays for detecting APP infections has become possible with the 
development of a variety of tests in recent years.  These assays detect antibody against either 
polysaccharide antigens, capsular polysaccharide, lipopolysaccharide, or Apx toxins (Inzana 
and Fenwick, 2001; Gottschalk et al., 1994; Nielsen, 2000).  In general, these techniques can 
be divided into those that are serovar or serogroup specific and those that are species-
specific, i.e., capable of detecting antibodies against all serovars of APP (Bossé et al., 1990; 
Dreyfus et al., 2004; Eamens et al., 2012; Gottschalk, 1994; Grondahl et al., 2003).   
 
Molecular techniques have been developed for the direct detection of APP (Cho and Chae, 
2001; Fittipaldi et al., 2003), but limitations have been reported with these techniques due to 
challenges in analytical sensitivity and specificity.  At this time, molecular techniques have 
primarily been used in research and not in routine diagnostics.  Presumably, molecular 
diagnostics will become more common as the technology develops.   
 
APP surveillance programs are the cornerstone for the control and/or eradication of the 
disease, but require the collection of samples from live pigs.  Current diagnostic methods for 
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antibody detection or culture require the collection of samples from individual pigs (serum, 
nasal, tonsil, or endotracheal swabs).  Alternatively, oral fluid specimens have proven to be 
useful for the detection of specific antibody and, therefore, highly suitable for the 
implementation of swine disease surveillance (Kittawornrat, et al., 2010; Ramirez et al., 
2012; Prickett et al.,  2008).  In this thesis we explore the use of an ApxIV antibody ELISA 
for the detection of ApxIV antibody in oral fluids.   
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Table 1.  Geographic distribution of Actinobacillus pleuropneumoniae serovars by region 
 
Region    Serovar Reference 
Eastern 
Europe 
1-13 Kucerova et al., 2005; Shabunin et al., 2013; Štukelj et 
al., 2014; Žutić et al., 2014. 
Western 
Europe 
 
1-12 Chiers et al., 2002; Gutiérrez-Martín et al., 2006; Kamp 
et al., 1997; Nielsen, 1988; O’Neill et al., 2015; Sjölund, 
2010. 
Asia  1-3, 5, 7, 8, 
12 
Fukuyasu et al., 1996; Lee et al., 2015; Torres et al., 
2008; Yang et al., 2011. 
North 
America 
1-3, 5-8, 10-
13, 15 
Fales et al., 1989; Gottschalk and Lacouture, 2015b; 
Gottschalk et al., 1994; MacInnes et al., 2008; Mittal et 
al., 1992; Ontiveros et al., 1995; Perry et al., 2012; 
Williams et al., 2000. 
South 
America  
1, 3-8, 12, 15 Kuchiishi et al., 2007; Pineda et al., 1996; Rodríguez-
Méndez, 2010; Zielinski, 2006. 
Australia 1-3, 5, 7, 15 Blackall et al., 1999; Blackall et al., 2002; Eaves and 
Blackall, 1998. 
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Table 2.  Actinobacillus pleuropneumoniae RTX toxins, function and serovar distribution. 
 
RTX toxins Function Serovar 
ApxI Strongly hemolytic and cytotoxic for 
alveolar macrophages and neutrophils 
1,5 (a,b), 9,10 and 11 
ApxII Weakly hemolytic and cytotoxic for 
macrophages and neutrophils 
1-9, 11-15 
ApxIII Non-hemolytic but strongly cytotoxic 
for alveolar macrophages and 
neutrophils 
2-4, 6 and 8 
ApxIV Still not clear, proven to be necessary 
for full virulence 
All serovars 
 
Data was compiled from: Beck et al., 1994; Chiers et al., 2010; Cho and Chae, 2001; Frey et 
al., 1993; Frey, 1995, 2003); Schaller et al., 1999.  
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CHAPTER 3.  DETECTION OF ACTINOBACILLUS PLEUROPNEUMONIAE 
APXIV TOXIN ANTIBODY IN SERUM AND ORAL FLUID SPECIMENS FROM 
PIGS INOCULATED UNDER EXPERIMENTAL CONDITIONS 
 
W Gonzalez, LG Giménez-Lirola, A Holmes, S Lizano, C Goodell,  
K Poonsuk, P Sitthicharoenchai, Y Sun, J Zimmerman 
 
Submitted to Journal of Veterinary Diagnostic Investigation 
 
SUMMARY 
The prevention and control of Actinobacillus pleuropneumoniae (APP) in commercial 
production settings is based on serological monitoring.  ELISAs have been developed to 
detect specific antibodies against a variety of APP antigens, including long-chain 
lipopolysaccharides (LPS) and the ApxIV toxin, an RTX exotoxin unique to APP and 
produced by all serovars.  The objective of this study was to describe ApxIV antibody 
responses in serum and oral fluid from 4 groups of pigs (6 pigs per group) inoculated with 
APP serovars 1, 5, 7, or 12.  Weekly serum samples and daily oral fluid samples were 
collected from individual pigs for 56 days post inoculation (DPI) and tested by LPS (IgG) 
and ApxIV ELISAs (IgM, IgA, IgG).  All pigs inoculated with APP serovars 1 and 7 were 
LPS ELISA serum antibody positive from DPI 14 to 56.  A transient and weak LPS ELISA 
antibody response was observed in pigs inoculated with serovar 5 and a single antibody 
positive pig was observed in serovar 12 at ≥ 35 DPI.  ApxIV serum and oral fluid antibody 
responses in pig inoculated with serovars 1 and 7 reflected the patterns observed for LPS 
antibody, albeit with a 14 to 21 day delay.  This work suggests that ELISAs based on ApxIV 
antibody detection in oral fluid samples could be effective in population monitoring for APP. 
 
INTRODUCTION 
Actinobacillus pleuropneumoniae (APP) is an important bacterial respiratory pathogen of 
swine causing acute fibrinohemorrhagic and necrotizing pleuropneumonia.51  In addition, 
APP is often involved in the porcine respiratory disease complex, a multifactorial infection 
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resulting from the combination of primary and secondary respiratory pathogens.3,4,17  
Transmission of APP to swine is commonly ascribed to exposure to contaminated respiratory 
secretions, and/or aerosols.11,56  More recent publications have described environmental 
contamination of commercial swine production systems with APP, which raises the 
possibility of indirect routes of transmission.32 
 
Two APP biotypes have been identified on the basis of the nicotinamide adenine dinucleotide 
(NAD or V-factor) requirement for growth: biotype I (NAD-dependent) and biotype II 
(NAD- independent).44  APP is further divided into 15 serovars on the basis of capsular 
polysaccharide antigen composition.  Serovars 1-to-12 and 15 belong to biotype 1; serovars 
13 and 14 to biotype 2.2,43  The degree of virulence among serovars is variable and dependent 
on several factors, including capsular polysaccharides (CP), lipopolysaccharides (LPS), outer 
membrane proteins, and the RTX exotoxins, e.g., ApxI, II, III, and IV, produced by all 
serovars albeit in different combinations.14,22,48  Apx toxins are highly immunogenic, i.e., 
induce antibody production.14,51 Importantly, the ApxIV toxin is unique to APP and is 
produced by all serovars.48 
 
The economic impact of APP on the swine industry is a consequence of chronic infections 
that reduce productivity, i.e., lower feed conversion rates or feed intake; infections that result 
in acute death, particularly in late finishers; lesions at slaughter; and the costs attributable to 
prevention, control, and/or elimination of APP.32,52  The prevention and control of the APP in 
commercial production settings is based on the detection of APP infections via serological 
monitoring.  Several APP serum antibody assays have been described and most are available 
for use in the diagnostic setting, including the complement fixation (CF) test, a variety of 
enzyme-linked immunosorbent assays (ELISA), and a fluorescent microsphere 
immunoassay.15  The CF is a technically complex assay with poor performance attributes 
(sensitivity and specificity), for which reasons it is used infrequently.17  In its place, ELISAs 
have been developed to detect specific antibodies against a variety of APP antigens 
including, capsular polysaccharide (CP), lipopolysaccharide (LPS), and Apx exotoxins 
(ApxI, II, III, IV).18,23,40 
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Although serum is the historic choice for antibody detection and APP surveillance, a variety 
of antibody-based assays for oral fluid specimens have been reported, e.g., assays for African 
swine fever virus,39 Erysipelothrix rhusiopathiae,16 influenza A virus,42 porcine circovirus 
type 2,45 and porcine reproductive and respiratory syndrome virus.28  The objective of the 
present study was to describe and compare antibody responses specific for ApxIV in serum 
and oral fluid from pigs inoculated with APP under experimental conditions using a 
commercial ApxIV antibody ELISA. 
 
MATERIALS AND METHODS 
Experimental design 
Four groups of pigs (6 pigs per group) were inoculated with APP serovars 1, 5, 7, or 12.  
Serum samples were collected weekly and oral fluid samples were collected daily from 
individual pigs from day post inoculation (DPI) -14 through DPI 56.  To confirm infection, 
serum samples were completely randomized and tested by long-chain lipopolysaccharide 
(LPS) ELISAs for serovars [(1(9, 11), 5a-5b, 7(4), and 12] at a Service de Diagnostic, 
University of Montreal, Québec, Canada.  Serum and oral fluid samples were tested for 
ApxIV antibody using a commercial assay.a  Statistical analyses were performed to compare 
the ApxIV responses among and within serovars over time.  The study was approved by the 
Iowa State University Office for Responsible Research (#8-13-7626-S, #13-I-0019-A). 
 
Animal management and housing 
The 24 14-week-old pigs used in the experiment were housed at the Iowa State University 
Livestock Infectious Disease Isolation Facility, a facility accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care.  All personnel involved in the 
experiment had received institutional approval for working with swine and conducting the 
procedures.  Animals were observed a minimum of twice daily throughout the experiment. 
 
Upon arrival, animals were randomly assigned to one of the four APP serovar groups by 
blindly selecting ear tags from a bag.  Each consecutive sequence of six ear tag numbers was 
assigned to one room (serovar).  Animals were weighed upon arrival using a portable 
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electronic scaleb for the purpose of assessing general health and group uniformity.  Pigs were 
individually housed in pens equipped with nipple drinkers and fed an antibiotic-free 
commercial dietc once daily.  Hard plastic ballsd were provided for enrichment.  Pigs were 
acclimatized for 2 weeks following placement in the facility, during which time they were 
trained for oral fluid collection.  At 58 DPI, pigs were humanely euthanized by penetrating 
captive bolte followed by exsanguination.31 
 
Sample collection 
To prevent cross-contamination, four people performed daily feeding and oral fluid sampling 
chores, i.e., one person for each room (serovar).  When it was necessary to move between 
rooms, e.g., for blood collection, personnel showered and changed coveralls, boots, gloves, 
masks, and protective eyewear between each room. 
 
Serum samples were collected weekly from DPI -14 through 56 using a single-use blood 
collection systemf and then centrifuged at 1800 x g for 10 min.  Samples were assigned a 
random number at the time of collection and stored in 2 ml aliquots at -80°C until tested. 
 
Oral fluid samples were collected daily from individual pigs as described elsewhere.27,46  In 
brief, 3-strand, 1/2" (1.27 cm) diameter, 100% cotton ropeg was suspended from a bracket 
fixed to the side of the pen to allow the pigs to chew on the rope.  After 30 min, the chewed 
(wet) end of the rope was inserted into a plastic bag and severed from the dry portion of the 
rope.  To harvest the fluid, the rope was passed through a wringerh while in the plastic bag.  
The fluid that accumulated in the bottom of the bag was then decanted into a 50 ml 
centrifuge tube.i  Samples were assigned a random number at the time of collection and 
stored in 4 ml aliquots -80°C until tested. 
 
Inoculum preparation 
Four strains of APP were used in this experiment:  serovar 1 (ATCC 27088), serovar 5a 
(ATCC 33377), serovar 7 (ATCC WF83), and serovar 12 (ATCC 9799/84).  For 
propagation, bacteria were cultured on chocolate agar platesj incubated at 35°C with 5-10% 
CO2 for 48 hrs.  To check for purity, bacterial isolates were streaked on 5% sheep blood agar 
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plates.j  Plates were then cross-streaked with Staphylococcus epidermidis and incubated at 
35°C for 48 hrs. 
 
Prior to preparing the inoculum, serovar identity was confirmed by co-agglutination.36  In 
brief, bacteria were harvested from chocolate agar plates and mixed with normal saline (~2.5 
ml) to a McFarland turbidity of 0.5.38  Thereafter, each bacterial suspension was dispensed 
onto plastic 3-well blood typing platesk at a rate of 3 drops per well to which was added one 
drop of each serovar-specific serotyping reagent to each well.30  After mixing on a 
mechanical rotatorl for 2 min at a speed of 140 rpm, the serovar was identified by 
agglutination of the bacterial suspension with a specific serotyping reagent.  Agglutination in 
more than one well was interpreted as an untypeable response.53 
 
To prepare the inoculum, bacteria was harvested from the chocolate agar plate and suspended 
in normal saline (~2.5 ml) to a McFarland turbidity of 0.5.  To estimate the bacterial 
concentration, 6 ten-fold serial dilutions (10-1 to 10-6) were made of the McFarland 
suspension into sterile saline.  10 µl of each dilution was pipetted onto a chocolate agar plate 
and streaked.  After 48 hrs of incubation, the numbers of colonies were counted and used to 
estimate colony forming units (CFU) per ml in the McFarland suspension.36, 53 
 
Inoculation and post-inoculation observations 
Prior to inoculation all animals tested negative for APP serum antibody by two commercial 
ELISAsa,m at the Iowa State University Veterinary Diagnostic Laboratory (Ames, Iowa). 
 
To reduce animal stress and facilitate handling, pigs were sedated immediately prior to 
inoculation using a solution formulated by reconstituting n 250 mg of tiletamine, 250 mg of 
zolazepam with 2.5 ml of xylazineo (100 mg per ml) and 2.5 ml of ketaminep (100 mg per 
ml).  An intramuscular dose of 0.05 ml per kg of body weight provided approximately 20 
min of sedation.  Each room of animals (n = 6) was inoculated with one APP serovar (1, 5, 7 
or 12).  Animals were inoculated by instilling 2 ml of the inoculum intranasally (IN) and then 
swabbing the tonsils of the soft palate with a 16" large-tip cotton swabq  saturated with 3 ml 
of the inoculum.  Visualization of the tonsils and the process of tonsil swabbing were 
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facilitated with the use of an oral speculum.  For the first 24 hrs post inoculation, animals 
were observed for clinical signs and rectal temperatures taken every three hrs by the same 
individual.  Thereafter, clinical observations were taken each morning at the time of oral 
fluid collection.  Any animal exhibiting respiratory distress, emesis, reluctance to stand, 
and/or a rectal temperature ≥ 41°C   (≥ 105°F) at two consecutive observations was 
intramuscularly treated with ampicillinr at a dose of 5 mg per kg. 
 
Serum antibody testing 
To confirm infection, serum samples were tested at the Service de Diagnostic University of 
Montreal (Québec, Canada) with four long-chain lipopolysaccharide (LPS) ELISAs designed 
to detect capsular serovars [(1(9,11), 5a-5b, 7(4), and 12]. 
 
To detect ApxIV IgG antibody, serum samples were tested at Iowa State University using a 
commercial indirect ELISA.a  The test was performed according to the manufacturer’s 
instructions and a positive response was defined as a sample-to-positive (S/P) ratio ≥ 0.5. 
 
S/P ratio = 
(sample OD  –  negative control mean OD) 
______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
(positive control mean OD  –  negative control mean OD) 
 
The manufacturer's protocol was also followed for the detection anti-ApxIV IgM and IgA, 
but the kit IgG secondary antibody conjugate was replaced with goat anti-pig IgM or IgA 
horseradish peroxidase-labeled conjugates  diluted 1:2000 and 1:15000, respectively. 
 
Oral fluid antibody testing 
Prior to antibody testing, oral fluid samples were processed to remove suspended particulates 
by adding one ml of sample to a tube containing 100 µl of a lyophilized coagulant 
formulation (proprietary).  Tubes were shaken for one min and centrifuged (4°C) at 1,200 x g 
for 3 min.  The supernatant tested for ApxIV antibody on a commercial serum antibody 
ApxIV ELISAa using protocols modified to detect ApxIV IgM, IgA, and IgG in oral fluids.  
Specifically, ELISA kit serum plate controls were diluted to an OD of 0.1 (negative control) 
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and 1.3 to 1.5 (positive control) and the ELISA kit IgG secondary antibody conjugate was 
replaced with goat anti-pig IgM, IgG, or IgA horseradish peroxidase-labeled conjugate s 
diluted to 1:2000, 1:3000, or 1:15000, respectively.  To perform the test, samples were 
diluted 1:2 with sample diluent,a 100 µl of each sample was added to each well, and the 
plates were incubated at 37°C for 120 min.  Plates were then washed 5 times, 100 µl of anti-
pig IgG, IgM, or IgA was added to each well, and the plates incubated at 37°C for 60 min.  
Thereafter, TMB substrate (100 µl) was added to each well and the plates incubated at room 
temperature for 15 min.  Stop solution (100 µl) was added to each well, after which the 
reaction was read at 450 nm on an ELISA plate reader.  The sample-to-positive (S/P) ratios 
were calculated for each sample using the formula provided by the kit’s manufacturer. 
 
Data analysis 
Analyses were done using commercial statistical software.t  The results of serological testing 
were expressed as least square mean values of optical densities and S/Ps by serovar, 
specimen, and antibody isotype.  Figures were created using commercial graphics software.u  
Antibody responses within and among serovars were compared using repeated measures 
ANOVA.  If a significant difference was detected, then a post hoc test with Bonferoni 
adjustment was done to compare serovars by DPI. 
 
RESULTS  
Clinical observations 
As shown in Table 1, the frequency with which clinical signs were observed varied among 
serovar groups.  No clinical signs were observed in pigs inoculated with serovar 12 at any 
time.  Some or all of serovar 5 pigs were reluctant to stand through DPI 2 to 4, but did not 
exhibit other clinical signs.  Pigs inoculated with serovars 1 or 7 exhibited clinical signs in 
the first 24 hrs post inoculation and through DPI 11, including panting, reluctance to move, 
vomiting, anorexia and rectal temperature ≥ 105°F (≥ 41°C).  All animals from these two 
groups were treated with ampicillin from DPI 4 through 11.  One pig inoculated with serovar 
1 was found dead the morning of DPI 3.  Post mortem examination revealed lesions 
characteristic of APP infection, i.e., tonsils covered in purulent exudate, trachea and bronchi 
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filled with a foamy exudate, and extensive pleural adhesions.  One pig from the serovar 7 
group was humanely euthanized on DPI 20 due to lameness unrelated to APP infection. 
 
Sample collection 
A total of 202 serum samples were collected from DPI 0 to 56, after which they were 
completely randomized and tested by 4 LPS ELISAs and the ApxIV ELISA.  A total of 1,311 
oral fluid samples were collected from DPI -8 to 56, with a mean sample volume of 8.22 ± 
5.6 ml (SD) per pig.  A subset of oral fluid samples (n = 1,264) were completely randomized 
and tested by ApxIV ELISA. 
 
LPS ELISA serum antibody responses 
Serum samples were tested by four LPS ELISAs [(1(9, 11), 5a-5b, 7(4), and 12], with 
positive results only observed against the serovar to which animals were exposed.  The LPS 
ELISA serum antibody response varied significantly among serovars (Figure 1, Table 2).  
Based on the manufacturer's recommended cutoff of OD ≥ 0.40, all but 2 samples from pigs 
exposed to serovars 1 (n = 5) and 7 (n = 6) were positive from DPI 14 through DPI 56.  In 
serovar 5, 4 of 6 pigs were positive at DPIs 14, 21, 28; 2 pigs were positive at DPI 35; and 
one pig was positive at DPI 42 and later.  In serovar 12, all pigs were negative, except for one 
pig that tested positive on DPIs 35, 42, and 49. 
 
Within serovars, comparisons showed that all serovar 1 OD responses at DPI ≥ 7 were higher 
than DPI 0 OD responses (p < 0.0001).  For serovars 5 and 7, ODs at DPI 14 and later were 
significantly higher than DPI 0 (p < 0.0001).  For serovar 12, pairwise comparisons found no 
difference in mean OD responses when compared to DPI 0 except for DPI 49 (p = 0.038). 
Between serovars, the magnitude of LPS OD responses differed significantly over time (p < 
0.0001).  Comparisons by DPI detected no difference between serovar 1 and 7 OD responses.  
At DPIs 14 through 56, serovar 1 and 7 responses were significantly higher than serovars 5 
and 12 (p < 0.0001).  At DPIs 14 through 42, serovar 5 OD responses were higher that 
serovar 12 (p < 0.0001). 
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ApxIV ELISA serum antibody responses (Table 3) 
ApxIV IgG ELISA          ApxIV serum antibody (IgG) ELISA S/P responses varied among 
serovars.  Based on the manufacturer's recommended cutoff (S/P ≥ 0.50), 3 of 5 pigs in 
serovar 1 and 5 of 5 pigs in serovar 7 became positive over the course of the study.  No pigs 
in serovars 5 or 12 met the manufacturer's criterion for positivity. 
 
Within serovars, all serovar 1 and 7 IgG ELISA S/P responses at DPI 21 and later were 
significantly higher than their DPI 0 S/P responses (p < 0.0001).  In serovars 5 and 12, 
pairwise comparisons found no difference in S/P responses by time when compared to DPI 0. 
 
A comparison among serovars showed that the serovar 1 IgG S/P response was higher than 
serovars 5 and 12 at DPI 28 and later (p < 0.0033).  The serovar 7 IgG S/P response was 
higher than the serovar 1 response at DPI 21 (p = 0.0090) and 56 (p = 0.0301) and higher 
than serovars 5 and 12 at DPI 14 and later (p < 0.0040).  No difference was detected in the 
serovar 5 and 12 responses over time. 
 
ApxIV IgM ELISA          Within serovars, serovar 1 and 7 IgM S/P responses were higher than 
DPI 0 responses at DPI 14 (p < 0.0001).  In serovars 5 and 12, no difference was found in 
IgM responses at any time point when compared to DPI 0.  Between serovars, the serovar 7 
IgM S/P response was higher than serovars 1, 5, and 12 at DPIs 14 and 21 (p < 0.0020).  
Serovar 1 IgM S/P responses differed from serovar 12 at DPI 14 (p = 0.0163) and DPI 42 (p 
= 0.0264). 
 
ApxIV IgA ELISA          Within serovars, comparisons detected IgA S/P responses higher than 
DPI 0 at DPI 56 (p = 0.0373) in pigs exposed to serovar 1.  Likewise, detectable differences 
were found on IgA responses in pigs exposed to serovars 5 at DPI 35 (p = 0.0485) and DPI 
42 (p = 0.0015).  No detectable differences were found on serovars 7 and 12 when compared 
with DPI 0.  Comparisons among serovars found no detectable difference in the magnitude of 
IgA S/P responses over time. 
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ApxIV ELISA oral fluid antibody responses (Table 4) 
ApxIV IgG ELISA          ApxIV oral fluid antibody (IgG) ELISA S/P responses varied among 
serovars.  In serovar 1, the IgG S/P responses were higher than DPI 0 on DPI 15 and later (p 
= 0.0096).  In serovar 5, IgG S/P responses higher than DPI 0 were detected at DPI 41 (p = 
0.0267).  In serovar 7, S/P responses greater than DPI 0 were detected at DPI 14 and later (p 
< 0.0313).  In serovar 12, no difference in IgG response was found at any sampling point 
when compared to DPI 0. 
 
Comparisons between serovars showed that the magnitude of the IgG S/P antibody response 
differed between serovars 1 and 7 at DPI 22 (p = 0.0229), DPI 35 (p = 0.0013) and later.  The 
serovar 1 IgG S/P response was higher than serovars 5 and 12 at DPI 16 and later (p < 
0.0403).  Likewise the serovar 7 response was higher than serovars 5 and 12 at DPI 15 and 
later (p < 0.0361).  No difference was detected in serovar 5 and 12 responses over time. 
 
ApxIV IgM ELISA          In serovar 1, IgM S/P responses were higher than DPI 0 at DPI 29 (p 
= 0.0157).  In serovar 5, IgM S/P responses were higher than DPI 0 at DPI 3 through 11 (p = 
0.0355), and at DPI 45 (p = 0.0163) through 56 (p = 0.0161).  In serovar 7, IgM responses 
were higher than DPI 0 at DPI 13 (p = 0.0261), DPI 14 (p = 0.0157) and DPI 15 (p < 
0.0001).  In serovar 12, no difference in IgM response was found at any sampling point when 
compared to DPI 0. 
 
Comparisons between serovars showed that the serovar 7 IgM S/P response was higher than 
serovars 1, 5 and 12 at DPIs 11 through 15 (p < 0.0488) and then higher than serovar 1 at 
DPI 43 (p = 0.0143) and DPI 46 (p < 0.0001).  The serovar 1 IgM S/P response was higher 
than serovar 12 at DPI 29 (p = 0.0139).  No difference was detected in serovar 5 and 12 
responses over time when compared to each other. 
 
ApxIV IgA ELISA          In serovar 1, IgA S/P responses were higher than DPI 0 at DPI 44 (p 
= 0.0482), 52 (p = 0.0371), and DPI 55 (p < 0.0001).  In serovar 7, IgA responses were 
higher from DPI 0 at DPIs 10 and 11(p = 0.0307), then on DPIs 14-19 (p < 0.0218), DPI 30-
56 (p < 0.0001).  No detectable differences were found on serovars 5 and 12 over time when 
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compared with DPI 0.  Comparisons between serovars detected no differences in the IgA S/P 
responses among serovars 1, 5, and 12 at any sampling point.  The serovar 7 IgA S/P 
response was higher than serovars 1, 5, and 12 at DPI 23 and later (p < 0.0001). 
 
DISCUSSION 
The goal of this study was to describe ApxIV-specific antibody responses in serum and oral 
fluid from pigs inoculated with APP under experimental conditions.  ApxIV is only produced 
by APP, is produced by all serovars, and is highly immunogenic, i.e., produces detectable 
levels of serum antibodies in pigs.8,12,21  For these reasons, ApxIV antibody offers the 
potential to monitor APP infections in the field.  Detection of ApxIV antibody has not been 
previously described in swine oral fluids, although oral fluid has been shown to be a suitable 
specimen for the detection of antibodies against a variety of pathogens, as reviewed 
elsewhere.27,46 
 
The outcome of inoculating pigs with APP under experimental conditions depends on the 
route and dose.1,49  Several routes of APP inoculation have been described, including IN,25,37 
endotracheal,1 endobrochial,26 direct application of the inoculum to the tonsils of the soft 
palate,7 and aerosol.19  Reproducing APP infections under experimental conditions is 
complicated by the fact that lower challenge doses may not result in infection.55,56  On the 
other hand, higher doses may cause severe clinical signs and/or acute death.47 
 
As distinct from experimental inoculation, APP infections in the field are believed to occur 
by direct contact between pigs or via aerosol exposure.11,17  However, recent research has 
shown that the environment (drinking water, feed, soil) is also heavily seeded with APP,32 
suggesting that field infections may involve repeated low-dose exposures.56  Thus, 
differences among experimental results may reflect variability in the exposure route and dose 
under experimental conditions24,25,55,56 and differences between experimental results and field 
observations may result from the fact that experimental exposures do not reflect the mode of 
APP transmission (dose, route, frequency) in the field.20 
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In the present study, animals were inoculated both IN and by direct application of the 
inoculum to the tonsils of the soft palate.  The production of clinical signs was marked and 
prolonged in the two groups (serovars 1 and 7) exposed to APP at a concentration of 1 x 106 
CFU per ml and mild or absent in groups exposed to APP at a concentration of 1 x 105 CFU 
per ml (serovars 5 and 12). 
 
The kinetics of the LPS-specific serum antibody response have been described.  After aerosol 
exposure to serovar 1, LPS-specific IgM was reported at 14 DPI, IgA at 14 to 21 DPI, and 
IgG at 21 DPI.5  Following IN exposure to serovar 9, LPS-specific IgM was detected at 7 
DPI and both IgA and IgG at 14 DPI.29  In the current study, the LPS serum antibody 
response in serovars 1 and 7 was in agreement with previous reports.  That is, an LPS-
specific IgG response was detected as early as 7 DPI, with all animals seropositive by DPI 
14.  Thereafter, all animals remained seropositive through DPI 56.  Thus, the LPS serum 
antibody ELISA response was compatible with "productive" APP infection in animals 
inoculated with serovars 1 and 7.  In contrast, a weak and transient LPS ELISA response was 
observed in animals inoculated with serovar 5.  In serovar 12, a single animal was LPS 
ELISA positive on DPI 35, 42, and 49.  These results are compatible with previous studies 
reporting variable success at infecting pigs with APP under experimental conditions,9,10 even 
at very high exposure doses.41,54 
 
There are relatively few studies on ApxIV serum antibody ontogeny and these are based on 
the detection of ApxIV-specific IgG.  ApxIV IgG was reported to be detected at 7 to 28 DPI 
in pigs inoculated with serovars 1, 5b, 6, 7, 10, or 15 via aerosol exposure.12  In other study, 
seroconversion to ApxIV  was reported at 3 to 6 weeks post inoculation in pigs exposed to 
serovars 1, 7, or 15 by either IN or endotracheal routes.13  In the current study, using the 
ApxIV ELISA S/P results from DPI 0 as the basis for comparison, a significant increase (p < 
0.05) in ApxIV antibody was detected in serum at 14 DPI (IgM) and 21 DPI (IgG) in animals 
inoculated with serovars 1 and 7.  This pattern was consistent with previous reports,12,13 and 
also followed the pattern observed for the LPS ELISA response in these animals. 
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The results of this study suggested that the S/P cutoff of the commercial serum ApxIV IgG 
ELISA is too high.  That is, using the manufacturer's recommended cutoff (S/P ≥ 0.50), 
"seroconversion" was delayed in some animals inoculated with serovars 1 or 7 up to DPI 49.  
However, a limitation of the current study was the small number of animals.  As a 
consequence, it was not possible to conduct a valid statistical analysis of test performance, 
e.g., receiver operating characteristic analysis, to re-calculate the ELISA cutoff and 
associated test sensitivity and specificity. 
 
In a previous report, APP IgA was detected in stimulated oral fluid samples collected 14 DPI 
after the IN inoculation of pigs with serovar 2, but there are no previous reports of ApxIV 
antibody in swine oral fluid.33  Using the oral fluid ApxIV ELISA S/P results from DPI 0 as 
the basis for comparison, a significant increase (p < 0.05) in ApxIV IgG S/P ratios was 
detected at ≥ 21 DPI in pigs inoculated with serovar 1, with no detectable increase in IgM or 
IgA.  In serovar 7, significantly higher IgG S/P ratios were observed at ≥ 14 DPI.  In this 
group, a significant increase (p < 0.05) in the ApxIV IgM response was observed at 14 DPI 
and in the IgA response at DPI 21 and then at ≥ 35 DPI. 
 
Respiratory diseases are among the most important issues in swine health worldwide.  
Among other determinants, the increasing intensification of pork production and the 
development of large, technified pig farms have created conditions suitable for the spread of 
agents associated with swine respiratory diseases.35  The development of tools for monitoring 
respiratory infections is a key component in the control of these diseases.  Previous studies 
have demonstrated the efficiency of swine oral fluids for the detection of antibody against 
ASFV, 39 influenza A virus, 42 porcine circovirus type 2,45 and porcine reproductive and 
respiratory syndrome virus 28 and others.  Based on the data presented herein, it can be 
concluded that assays for detecting APP ApxIV antibody in oral fluids could also be 
developed for monitoring APP infections in commercial herds. 
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Table 1.   Clinical observations following inoculation with Actinobacillus pleuropneumoniae  
 
  Day Post Inoculationa 
 OBSERVATION 0b 1 2 3 4 5 6 7 
S
er
o
v
a
r 
1
 
Reluctant to stand  6 6 6 5 4 4 1 1 
Respiratory distress 6 6 6 5 5 5 5 5 
Emesis 5 5 5 5 5 5 5 5 
Rectal temperature ≥41 C  1 •c • • • • • • 
Anorexia  6 • 6 5 5 2 2 0 
Oral Fluid collection (≥1 ml) 4 0 0 1 2 3 3 3 
S
er
o
v
a
r 
5
 
Reluctant to stand 6 6 6 2 2 • • • 
Respiratory distress • • • • • • • • 
Emesis  • • • • • • • • 
Rectal temperature ≥41 C • • • • • • • • 
Anorexia  • • • • • • • • 
Oral Fluid collection (≥1 ml) 6 3 3 5 5 4 5 4 
S
er
o
v
a
r 
7
 
Reluctant to stand 6 6 6 6 6 6 6 6 
Respiratory distress 6 6 6 6 6 6 6 6 
Emesis  6 6 6 2 2 • • • 
Rectal temperature ≥41 C 1 • • • • • • • 
Anorexia  6 6 6 6 6 6 6 6 
Oral Fluid collection (≥1 ml) 5 0 0 0 0 3 5 0 
S
er
o
v
a
r 
1
2
 
Reluctant to stand • • • • • • • • 
Respiratory distress • • • • • • • • 
Emesis  • • • • • • • • 
Rectal temperature ≥41 C • • • • • • • • 
Anorexia  • • • • • • • • 
Oral Fluid collection (≥1 ml) 6 5 6 6 5 6 6 5 
 
a Denominator is 6 pigs in all groups at all DPIs, except serovar 1 (one pig died on DPI 2). 
b First 24 hours following inoculation. 
c Symbol (•) indicates not observed in any pigs in the group. 
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Table 2.   Actinobacillus pleuropneumoniae qualitative serum antibody responses by serovar 
over time based on serogroup capsular LPS ELISAsa 
 
  
Pig 
status 
Day Post Inoculation 
APP Inoculum  LPS ELISA 0 7 14 21 28 35 42 49 56 
Serovar 1 
ATCC 27088 
1-9-10-11 positive 1 3 5 4 4 5 5 5 5 
 suspect 0 1 0 0 0 0 0 0 0 
  negative 5 1 0 1 1 0 0 0 0 
  no. pigs 6 5 5 5 5 5 5 5 5 
Serovar 5 
ATCC 33377 
5a-5b positive  0 0 4 4 4 2 1 1 1 
 suspect 0 0 1 1 1 3 4 2 1 
  negative 6 6 1 1 1 1 1 3 4 
  no. pigs 6 6 6 6 6 6 6 6 6 
Serovar 7  
ATCC WF83 
4-7 positive  0 1 6 6 5 5 5 4 5 
 suspect 0 4 0 0 0 0 0 0 0 
  negative 6 1 0 0 0 0 0 0 0 
  no. pigs 6 6 6 6 5 5 5 5b 5 
Serovar 12 
ATCC 9799/84 
12 positive  0 0 0 0 0 1 1 1 0 
 suspect 0 0 0 0 0 0 0 0 0 
  negative 6 6 6 6 6 5 5 5 5 
  no. pigs 6 6 6 6 6 6 6 6 6b 
 
aAPP LPS ELISA interpretation based on optical density (OD):  negative  OD < 0.30, suspect 
OD 0.30 - 0.39, positive OD ≥ 0.40. 
b Missing data on one pig.
  
 
     Table 3.   Actinobacillus pleuropneumoniae ApxIV serum antibody ELISA (S/P) response over time 
 
  Day Post Inoculation 
APP Inoculum  Isotype 0 7 14 21 28 35 42 49 56 
Serovar 1 
ATCC 27088 
IgM 0.02 0.23 0.43a 0.29a 0.27a 0.35a 0.47a 0.41a 0.29a 
IgA 0.03 0.08 0.12 0.14 0.19 0.18 0.11 0.34 0.37a 
IgG -0.03 -0.00 0.09 0.12a 0.29a 0.49a 0.47a 0.58a 0.53a 
Serovar 5 
ATCC 33377 
IgM 0.12 0.34 0.29 0.23 0.17 0.19 0.32 0.17 0.31 
IgA 0.05 0.11 0.16 0.17 0.19 0.35a 0.53a 0.31 0.29 
IgG -0.02 -0.00 -0.01 -0.00 -0.00 -0.00 0.01 0.00 0.02 
Serovar 7  
ATCC WF83 
IgM 0.19 0.20 1.32a 0.73a 0.44a 0.38a 0.35a 0.33a 0.25a 
IgA -0.01 0.00 0.03 0.07 0.14 0.11 0.16 0.08 0.05 
IgG -0.02 -0.00 0.24 0.36a 0.38a 0.46a 0.44a 0.63a 0.73a 
Serovar 12 
ATCC 9799/84 
IgM 0.01 0.02 0.02 0.05 0.18 0.23 0.09 0.14 0.17 
IgA 0.19 0.27 0.44 0.39 0.29 0.08 0.27 0.42 0.18 
IgG -0.2 -0.02 -0.02 -0.02 0.02 0.02 -0.02 -0.02 -0.03 
 
  aWithin serovars, S/P responses were significantly higher than DPI 0 responses ( ANOVA, p < 0.05) 
 
  
         5
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     Table 4.  Actinobacillus pleuropneumoniae ApxIV oral fluid antibody ELISA (S/P) response over time 
 
  Day Post Inoculation 
APP Inoculum  Isotype 0 7 14 21 28 35 42 49 56 
Serovar 1 
ATCC 27088 
IgM 0.05 0.07 0.06 0.15 0.05 0.04 0.04 0.02 0.02 
IgA 0.07 0.16 0.10 0.12 0.11 0.10 0.13 0.12 0.19 
IgG 0.00 0.01 -0.00 0.17a 0.23a 0.24a 0.42a 0.25a 0.21a 
Serovar 5 
ATCC 33377 
IgM 0.07 0.03 0.06 0.06 0.13 0.05 0.05 0.03 0.02 
IgA 0.03 0.04 0.05 0.05 0.10 0.08 0.20 0.06 0.08 
IgG -0.01 -0.01 -0.00 0.00 0.00 -0.00 0.00 -0.01 -0.00 
Serovar 7  
ATCC WF83 
IgM 0.09 0.13 0.39a 0.11 0.13 0.17 0.05 0.06 0.07 
IgA 0.00 0.23 0.25a 0.11 0.30 0.56a 0.46a 0.39a 0.47a 
IgG -0.03 0.06 0.17a 0.23a 0.29a 0.60a 0.43a 0.41 a 0.47a 
Serovar 12 
ATCC 9799/84 
IgM 0.04 0.11 0.06 0.06 0.05 0.07 0.05 0.02 0.02 
IgA 0.04 0.10 0.08 0.08 0.09 0.12 0.08 0.05 0.07 
IgG 0.01 0.01 0.01 0.01 0.00 0.01 0.00 -0.00 -0.00 
 
             aWithin serovars, S/P responses were significantly higher than DPI 0 responses ( ANOVA, p < 0.05) 
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Figure 1.  Actinobacillus pleuropneumoniae quantitative serum antibody responsesa (least 
square means) by serovar over time based on serogroup LPS ELISAs.   
 
a APP LPS ELISA interpretation is based on optical density (OD):  negative OD < 0.30, 
suspect OD 0.30 - 0.39, positive OD ≥ 0.40. 
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CHAPTER 4.  GENERAL CONCLUSIONS 
Actinobacillus pleuropneumoniae (APP), the causative agent of porcine pleuropneumonia, is 
found throughout the world and may be a significant health issue wherever swine are 
produced commercially (Sebunya and Saunders, 1983).  APP infections are often acute and 
rapidly fatal, but animals can also develop chronic and/or subclinical infections which are 
important because then can serve to seed future outbreaks (Gottschalk, 2012).   
 
Interest in APP arose with the recognition of the considerable economic losses attributable to 
the disease, including the costs of identifying infected herds (Gottschalk, 2012; Losinger, 
2005).  Several preventive measures have been described and, with some limitations, are 
considered effective (Gottschalk, 2012; MacInnes et al., 1988; Sebunya and Saunders, 1983).   
 
Overall, APP has been (and remains) an “under-studied” pathogen, i.e., funding for research 
has been minimal.  This may be justified by the perception that foreign, transboundary, or 
emerging viral pathogens pose a greater threat (directly or indirectly) to the industry.  
Whether this will still be true as the use of antimicrobials in veterinary medicine become 
more restricted remains to be seen.  Even so, APP is a clinical and economic problem in 
many parts of the world and in some North American swine production systems.  If control 
or elimination of APP is to be achieved in such circumstances, specific information and/or 
technology is needed.  In particular, a review of the literature shows that a better and more 
complete understanding of the epidemiology and ecology of APP is needed.   
 
As the industry continues to consolidate, the development of tools for monitoring respiratory 
infections will be a key component in the control of these diseases.  Previous studies have 
demonstrated the efficiency of swine oral fluids for the detection of antibody against ASFV 
(Mur et al., 2013), influenza A virus (Panyasing et al., 2013), porcine circovirus type 2 
(Prickett et al., 2008), and porcine reproductive and respiratory syndrome virus (Kittawornrat 
et al., 2012) and others.  Based on the data presented herein, it can be concluded that assays 
for detecting APP ApxIV antibody in oral fluids could also be developed for monitoring APP 
infections in commercial herds and should be a priority for future research. 
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